Ensign Peak Advisors
APGE

Ensign Peak Advisors’s Apogee Therapeutics APGE Stock Holding History

Ensign Peak Advisors’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$299K Sell
2,250
-80,050
-97% -$7.21M ﹤0.01% 1179
2026
Q1 		$6.93M Buy
82,300
+80,050
+3,558% +$5.81M 0.01% 476
2025
Q4 		$170K Buy
+2,250
New +$142K ﹤0.01% 1380
2025
Q1 		– Sell
-69,750
Closed -$3.16M – 1690
2024
Q4 		$3.16M Hold
69,750
– – 0.01% 781
2024
Q3 		$4.1M Hold
69,750
– – 0.01% 696
2024
Q2 		$2.74M Buy
69,750
+57,750
+481% +$2.8M 0.01% 793
2024
Q1 		$797K Buy
+12,000
New +$524K ﹤0.01% 1467

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Ensign Peak Advisors's APGE Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Apogee Therapeutics (APGE) stake by 97% in Q2 2026, selling an estimated $7.21M and leaving 2,250 shares worth $299K. The position accounts for ﹤0.01% of the portfolio, ranked #1179.

Ensign Peak Advisors first reported a position in APGE in Q1 2024 and has held it in 7 quarters since. The position peaked at $6.93M in Q1 2026. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Ensign Peak Advisors held 2,250 shares of Apogee Therapeutics worth $299K as of Q2 2026.
  • Ensign Peak Advisors sold 80,050 Apogee Therapeutics shares in Q2 2026, an estimated $7.21M.
  • Apogee Therapeutics made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #1179 holding.
  • Ensign Peak Advisors first reported a position in Apogee Therapeutics in Q1 2024 and has held it in 7 quarters since.
  • Ensign Peak Advisors's Apogee Therapeutics position peaked at $6.93M in Q1 2026.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.